Skip to main content

Advertisement

Log in

Upstaging of melanoma in situ and lentigo maligna treated with Mohs micrographic surgery rarely results in additional surgical management

  • Concise Communication
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

As Mohs micrographic surgery (MMS) is more widely utilized for melanoma in situ (MIS) and lentigo maligna (LM), there is increasing concern over whether the procedure can negatively affect the treatment of upstaged tumors. Previous studies have shown that about 1–2% of MIS/LM treated with MMS require sentinel lymph node biopsy, but little is still known regarding surgical outcomes. We performed a retrospective chart review of 117 MIS/LM lesions treated with MMS at Brigham and Women’s Hospital. We found a low rate of tumor upstaging (8.5% or 10/117), and only 1.7% (2/117) required wide local excision and sentinel lymph node biopsy. In both patients, there was successful location of the sentinel nodes by surgical oncologists. This study highlights the low risk of MIS/LM upstaging, with the majority changing to T1a, and the low need for further surgical management after MMS. Collaboration with other surgical specialties ensures appropriate management of patients with upstaged tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Nosrati A, Berliner JG, Goel S et al (2017) Outcomes of Melanoma in situ treated with Mohs micrographic surgery compared with wide local excision. JAMA Dermatol 153(5):436–441

    Article  Google Scholar 

  2. Kunishige JH, Doan L, Brodland DG, Zitelli JA (2019) Comparison of surgical margins for lentigo maligna versus melanoma in situ. J Am Acad Dermatol. 81:204–212

    Article  Google Scholar 

  3. Iorizzo LJ 3rd, Chocron I, Lumbang W, Stasko T (2013) Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in situ. Dermatol Surg 39(3 Pt 1):365–371

    Article  CAS  Google Scholar 

  4. Etzkorn JR, Sobanko JF, Elenitsas R et al (2015) Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. J Am Acad Dermatol 72(5):840–850

    Article  CAS  Google Scholar 

Download references

Funding

Dr. Waldman is supported by a career development award from the Dermatology Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Abigail H. Waldman.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

IRB approval status

Approved by the Partners Human Research Office.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Levoska, M.A., Schmults, C.D. & Waldman, A.H. Upstaging of melanoma in situ and lentigo maligna treated with Mohs micrographic surgery rarely results in additional surgical management. Arch Dermatol Res 312, 753–756 (2020). https://doi.org/10.1007/s00403-020-02034-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-020-02034-9

Keywords

Navigation